???global.info.a_carregar???
I’m a post-doctoral researcher with over 15 years of experience in cellular and molecular biology applied to cancer research. I completed my degree and MSc in Pharmacy at the University of Coimbra in Portugal. In 2008, I was awarded a fellowship for a short-term stay at Dr. Enrique de Alava’s group in Salamanca, where a few years later I obtained a Ph.D. fellowship granted by Fundação para a Ciência e Tecnologia, from Portugal. After earning my Ph.D. in cancer molecular biology from the Cancer Research Center-Universidad de Salamanca, I joined Dr. Enrique de Álava’s new group in Seville. I have been a post-doctoral fellow at the Institute of Biomedicine of Seville, working in close touch with the clinical setting of pediatric sarcomas. Additionally, I earned an MSc degree in Clinical Trials from the University of Seville. During my post-doctoral stage, I had the chance to work at the Institute of Cancer Research, in London, under the supervision of Dr. Janet Shipley, generating 3D models and optimizing new in vitro invasion protocols. Recently, I’ve been enjoying a visiting research grant at Dr. João Moreira’s group, the Tumor Microenvironment, and Targeted Therapies group at the CNC-Universidade de Coimbra, in Portugal. During the last few years, my research has been focused on the tumoral microenvironment (transmembrane proteins and extracellular vesicles) and the development of new in vitro and in vivo research models to better understand the biology underlying the tumoral progression of rare pediatric sarcomas. In particular, I have established a new research line, focused on the study of desmoplastic small round cell tumors, and am currently developing genetically engineered models to mimic this disease I have obtained individual funding to carry out my projects and had the opportunity to supervise several MSc and Ph.D. students. My motivation has been and will always be directed towards improving the clinical outcome of patients and effectively translating molecular findings to the clinical setting.
Identificação

Identificação pessoal

Nome completo
Ana Teresa Amaral

Nomes de citação

  • Amaral, Ana

Identificadores de autor

Ciência ID
FD1F-F6B7-E53E
ORCID iD
0000-0001-7887-4814
Google Scholar ID
https://scholar.google.com/citations?user=mJF59dYAAAAJ&hl=pt-PT

Websites

Domínios de atuação

  • Ciências Médicas e da Saúde - Biotecnologia Médica - Diagnóstico e Terapias de Base Genética

Idiomas

Idioma Conversação Leitura Escrita Compreensão Peer-review
Português (Idioma materno)
Inglês Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2)
Espanhol; Castelhano Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2) Utilizador proficiente (C2)
Italiano Utilizador independente (B1) Utilizador independente (B1) Utilizador elementar (A2) Utilizador independente (B1) Utilizador elementar (A1)
Francês Utilizador elementar (A2) Utilizador elementar (A2) Utilizador elementar (A2) Utilizador independente (B1) Utilizador elementar (A1)
Formação
Grau Classificação
2014 - 2015
Concluído
Clinical Trials (Master)
Universidad de Sevilla, Espanha
8.3/10
2009 - 2014/09/18
Concluído
Biologia Molecular y Clínica del Cancer (Doctor of Philosophy)
Especialização em Biologia Molecular y Clínica del Cancer
Universidad de Salamanca, Espanha

Instituto de Biología Molecular y Celular del Cáncer, Espanha
"The pathogenesis of Ewing Sarcoma: Implications of Mesenchymal Stem Cells and New Therapeutic Strategies" (TESE/DISSERTAÇÃO)
Sobresaliente, Cum Laude
2008/09 - 2010/12
Concluído
Biologia molecular y Clinica del Cancer (DEA)
Especialização em Molecular oncology
Universidad de Salamanca, Espanha
"Estudio de la Célula Stem Mesenquimal en Sarcoma de Ewing" (TESE/DISSERTAÇÃO)
2002 - 2008
Concluído
Ciências Farmacêuticas (Mestrado integrado)
Universidade de Coimbra Faculdade de Farmácia, Portugal
15
Percurso profissional

Ciência

Categoria Profissional
Instituição de acolhimento
Empregador
2024/09/01 - Atual Investigador Auxiliar (carreira) (Investigação) Tumor Microenvironment and Targeted Therapies group-CNC-UC, Portugal
ERA Fellowships - European Research Executive Agency, Portugal
2021 - Atual Gestão de Ciência e Tecnologia España Ministerio de Ciencia e Innovación, Espanha
2023/05/04 - 2024/08/31 Investigador Auxiliar (carreira) (Investigação) Universidade de Coimbra Instituto de Investigação Clínica e Biomédica de Coimbra, Portugal
2023/03/01 - 2023/04 Gestão de Ciência e Tecnologia Nordic Innovators P/S, Dinamarca
2014/12/31 - 2022/12/31 Investigador Auxiliar (carreira) (Investigação) Instituto de Biomedicina de Sevilla, Espanha
Instituto de Biomedicina de Sevilla, Espanha
2022/09/01 - 2022/12/01 Investigador visitante (Investigação) Universidade de Coimbra, Portugal
Tumor Microenvironment and Targeted Therapies group-CNC-UC, Portugal
2018/09 - 2018/12 Investigador visitante (Investigação) The Institute of Cancer Research, Reino Unido
The Institute of Cancer Research, Reino Unido
2009 - 2014 Investigador (Investigação) Instituto de Biología Molecular y Celular del Cáncer, Espanha
Instituto de Biología Molecular y Celular del Cáncer, Espanha
2008 - 2009 Estagiário de Investigação (Investigação) Instituto de Biología Molecular y Celular del Cáncer, Espanha
Instituto de Biología Molecular y Celular del Cáncer, Espanha
Projetos

Bolsa

Designação Financiadores
2024/01/09 - 2026/08/31 ERA Fellowships (HORIZON-WIDERA-2022-TALENTS-04)
Investigador Pós-doutorado
2022/01/01 - 2023 Tailored adoptive cellular immunotherapy for Ewing Sarcoma
Investigador Pós-doutorado
Instituto de Biomedicina de Sevilla, Espanha

Fundación Josep Carreras contra la Leucemia, Espanha
Obra Social La Caixa
Em curso

Projeto

Designação Financiadores
2023/05/01 - 2024/08/31 CInTech: Technological Hub for Innovation, Translation and Industrialization of Complex Injectable Drugs
Bolseiro de Pós-Doutoramento
Universidade de Coimbra, Portugal

Bluepharma, Portugal
Em curso
2021 - 2023 Integrative molecular-testing platform for precision diagnostics and personalized care of sarcoma patients
Investigador Pós-doutorado
Instituto de Biomedicina de Sevilla, Espanha

Hospital Universitario Virgen del Rocío, Espanha
Fundacion Maripaz Jimenez Casado
Em curso
2020 - 2023 Study of the prognostic and functional role of mesenchymal stem cell markers Endoglin and ALCAM in the disease progression of Clear cell sarcomas (CCS) and Desmoplastic small Round cell tumors (DSRCT)
P18-RT-735
Investigador responsável
Instituto de Biomedicina de Sevilla, Espanha
Junta de Andalucía
Concluído
2020 - 2023 New insights into the Desmoplastic small round cell tumour: comprehensive molecular characterization to identify therapeutic targets and new biomarkers
400300200313
Investigador responsável
Instituto de Biomedicina de Sevilla, Espanha
Grupo Espanol Investigacion Sarcomas
Em curso
2019 - 2023 Translational assessment of predictive factors of response of Ewing sarcoma to genotoxic therapy
S1900239
Investigador responsável
Instituto de Biomedicina de Sevilla, Espanha

Hospital Universitario Virgen del Rocío, Espanha

University College London, Reino Unido

University of Michigan, Estados Unidos
Sarcoma Foundation of America
2019 - 2022/12 CIBERONC-Centro de Investigacio Biomedica en RED: Low prevalence tumours program
Investigador Pós-doutorado
Centro de Investigación Biomédica en Red de Cáncer, Espanha
Em curso
2021 - 2022 Intratumoral heterogeneity in t-sarcomas: A silver lining for precision therapeutics
PI20-0003
Investigador Pós-doutorado
Instituto de Biomedicina de Sevilla, Espanha
Instituto de Salud Carlos III
Em curso
2020 - 2022 Evaluación de STAT6 como biomarcador de diagnóstico de precisión y diana terapéutica en Tumor Fibroso Solitario
PI-0061-2020
Investigador Pós-doutorado
Instituto de Biomedicina de Sevilla, Espanha

Hospital Universitario Virgen del Rocío, Espanha
Junta de Andalucía
Em curso
2018 - 2021 Evaluation of the clinical potential of the vesicular crosstalk in response to drugs in the context of Ewing sarcoma. PI-0040-2017
PI-0040-2017
Investigador responsável
Instituto de Biomedicina de Sevilla, Espanha
Junta de Andalucía
2018 - 2020 Nuevas dianas terapéuticas en el sarcoma de Ewing a través del estudio del proceso metastásico
PI1700464
Investigador Pós-doutorado
Instituto de Biomedicina de Sevilla, Espanha
Instituto de Salud Carlos III
Concluído
2018 - 2019 PROYECTO 3D-ID CULTIVOS 3D PERSONALIZADOS PARA SELECCIÓN DE TRATAMIENTO PARA PACIENTES DE CÁNCER EN MEDICINA DE PRECISIÓN
Investigador Pós-doutorado
Instituto de Biomedicina de Sevilla, Espanha

STEMTEK THERAPEUTICS SL, Espanha

FUNDACIÓN ONKOLOGIKOA FUNDAZIOA, Espanha

Institut d'Investigació Biomèdica de Bellvitge, Espanha
Desativado
2017 - 2018 PROspective VAlidation of Biomarkers in Ewing Sarcoma for personalized translational medicine
Investigador Pós-doutorado
Hospital Universitario Virgen del Rocío, Espanha

IRCCS Istituto Ortopedico Rizzoli, Itália

St James's University Hospital, Reino Unido

Institut Curie, França

Klinikum rechts der Isar der Technischen Universität München, Alemanha
European Commission
Concluído
2014 - 2017 Nuevas dianas terapéuticas en el sarcoma de Ewing: estudio del micromedioambiente
PI14/01466
Investigador Pós-doutorado
Instituto de Biomedicina de Sevilla, Espanha
Instituto de Salud Carlos III
Concluído
2014 - 2016 ENDOWING RELEVANCIA DE LA ENDOGLINA EN LA PATOLOGÍA DEL SARCOMA DE EWING: DESARROLLO DE TRATAMIENTOS PERSONALIZADOS INNOVADORES
Investigador Pós-doutorado
Instituto de Biomedicina de Sevilla, Espanha

Oncomatryx, Espanha
Concluído
Produções

Publicações

Artigo em revista
  1. Ana Amaral; Carmen Salguero Aranda; Joaquín Olmedo-Pelayo; Enrique de Alava; Ana Teresa Amaral; Juan Diaz-Martin. "Genetic Alterations and Deregulation of Hippo Pathway as a Pathogenetic Mechanism in Bone and Soft Tissue Sarcoma". Cancers 14 24 (2022): 6211-6211. http://dx.doi.org/10.3390/cancers14246211.
    10.3390/cancers14246211
  2. Puerto-Camacho, Pilar; Díaz-Martín, Juan; Olmedo-Pelayo, Joaquín; Bolado-Carrancio, Alfonso; Salguero-Aranda, Carmen; Jordán-Pérez, Carmen; Esteban-Medina, Marina; et al. Autor correspondente: Amaral, Ana Teresa. "Endoglin and MMP14 Contribute to Ewing Sarcoma Spreading by Modulation of Cell–Matrix Interactions". International Journal of Molecular Sciences 23 15 (2022): 8657. http://dx.doi.org/10.3390/ijms23158657.
    Acesso aberto • Publicado • 10.3390/ijms23158657
  3. Martí, Juan Manuel; Garcia-Diaz, Angel; Delgado-Bellido, Daniel; O'Valle, Francisco; González-Flores, Ariannys; Carlevaris, Onintza; Rodríguez-Vargas, José Manuel; et al. "Selective modulation by PARP-1 of HIF-1a-recruitment to chromatin during hypoxia is required for tumor adaptation to hypoxic conditions". Redox Biology 41 (2021): 101885. http://dx.doi.org/10.1016/j.redox.2021.101885.
    10.1016/j.redox.2021.101885
  4. González Muñoz, Teresa; Amaral, Ana Teresa; Puerto-Camacho, Pilar; Peinado, Héctor; de Álava, Enrique. "Endoglin in the Spotlight to Treat Cancer". International Journal of Molecular Sciences 22 6 (2021): 3186. http://dx.doi.org/10.3390/ijms22063186.
    10.3390/ijms22063186
  5. "Hippo pathway effectors YAP1/TAZ induce an EWS–FLI1 -opposing gene signature and associate with disease progression in Ewing sarcoma". The Journal of Pathology 250 4 (2020): 374-386. http://dx.doi.org/10.1002/path.5379.
    10.1002/path.5379
  6. "Breakthrough Technologies Reshape the Ewing Sarcoma Molecular Landscape". Cells 9 4 (2020): 804-804. http://dx.doi.org/10.3390/cells9040804.
    10.3390/cells9040804
  7. "Preclinical Efficacy of Endoglin-Targeting Antibody–Drug Conjugates for the Treatment of Ewing Sarcoma". Clinical Cancer Research 25 7 (2019): 2228-2240. http://dx.doi.org/10.1158/1078-0432.ccr-18-0936.
    10.1158/1078-0432.ccr-18-0936
  8. "DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma". Nature Medicine 23 3 (2017): 386-395. http://dx.doi.org/10.1038/nm.4273.
    10.1038/nm.4273
  9. "Ex vivo identification and characterization of a population of CD13high CD105+ CD45- mesenchymal stem cells in human bone marrow". Stem Cell Research & Therapy 6 1 (2015): http://dx.doi.org/10.1186/s13287-015-0152-8.
    10.1186/s13287-015-0152-8
  10. "The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin". Oncotarget 6 22 (2015): 18875-18890. http://dx.doi.org/10.18632/oncotarget.4303.
    10.18632/oncotarget.4303
  11. "Bone microenvironment signals in osteosarcoma development". Cellular and Molecular Life Sciences 72 16 (2015): 3097-3113. http://dx.doi.org/10.1007/s00018-015-1918-y.
    10.1007/s00018-015-1918-y
  12. "Trabectedin Efficacy in Ewing Sarcoma Is Greatly Increased by Combination with Anti-IGF Signaling Agents". Clinical Cancer Research 21 6 (2015): 1373-1382. http://dx.doi.org/10.1158/1078-0432.ccr-14-1688.
    10.1158/1078-0432.ccr-14-1688
  13. "Characterization of Human Mesenchymal Stem Cells from Ewing Sarcoma Patients. Pathogenetic Implications". PLoS ONE 9 2 (2014): e85814-e85814. http://dx.doi.org/10.1371/journal.pone.0085814.
    10.1371/journal.pone.0085814
  14. "Innovative Therapies in Ewing Sarcoma". Advances in Anatomic Pathology 21 1 (2014): 44-62. http://dx.doi.org/10.1097/pap.0000000000000003.
    10.1097/pap.0000000000000003
  15. "IGF1R Signaling in Ewing Sarcoma Is Shaped by Clathrin-/Caveolin-Dependent Endocytosis". PLoS ONE 6 5 (2011): e19846-e19846. http://dx.doi.org/10.1371/journal.pone.0019846.
    10.1371/journal.pone.0019846
  16. "The Clinical Relevance of Molecular Genetics in Soft Tissue Sarcomas". Advances in Anatomic Pathology 17 3 (2010): 162-181. http://dx.doi.org/10.1097/pap.0b013e3181d98cbf.
    10.1097/pap.0b013e3181d98cbf
  17. "Stable interference of EWS–FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target". British Journal of Cancer 101 1 (2009): 80-90. http://dx.doi.org/10.1038/sj.bjc.6605104.
    10.1038/sj.bjc.6605104
Poster em conferência
  1. Joaquin Olmedo-Pelayo; Amaral, Ana; Álava, Enrique De. "EWS::FLI1-DHX9 interaction alters R-loop metabolism promoting Ewing sarcoma sensitivity to genotoxic agents". Trabalho apresentado em ANNUAL CONGRESS OF THE EUROPEAN ASSOCIATION FOR CANCER RESEARCH EACR 2023, 2023.
  2. Lobo-Selma, Laura; Amaral, Ana; Carmen Salguero Aranda; Álava, Enrique De. Autor correspondente: Carmen Salguero Aranda. "Unravelling the molecular landscape of Desmoplastic Small Round Cell Tumor". Trabalho apresentado em ANNUAL CONGRESS OF THE EUROPEAN ASSOCIATION FOR CANCER RESEARCH EACR 2023, 2023.
Pré-impressão
  1. Ana Amaral; DANIEL DELGADO BELLIDO; Esteban Zamudio-Martínez; Monica Fernandez-Cortes; Ana Belen Herrera-Campos; Joaquin Olmedo-Pelayo; Carmen Jordan-Perez; et al. "VE-Cadherin modulates ß-catenin/TCF-4 to enhance Vasculogenic Mimicry". 2022. http://dx.doi.org/10.21203/rs.3.rs-2069549/v1.
    10.21203/rs.3.rs-2069549/v1
Atividades

Apresentação oral de trabalho

Título da apresentação Nome do evento
Anfitrião (Local do evento)
2023/11/14 Unraveling gene fusion dependent transcription factors in Desmoplastic Small Round Cell Tumor ASEICA 40th Anniversary Congress,
ASEICA (Coruña, Espanha)
2021/12/14 Desmoplastic Small Round Cell Tumor on the spotlight- Senior Author-Oral Presentation Desmoplastic Small Round Cell Tumor on the spotlight
CIBERONC (barcelona, Espanha)
2021/12/13 Dissecting the role of Rloops in Ewing sarcoma chemosensitivity- Contributing Author- Face to Face poster IV Young Researchers Meeting CIBERONC-BBN
CIBERONC (barcelona, Espanha)
2021 Circulating Biomarkers in Sarcomas with Translocations https://www.youtube.com/watch?v=ARO08iHZGBc&t=940s Precision diagnostics and follow-up of sarcoma patients
Asociación Sarcomas de Galicia (Galician Sarcoma Association) ASARGA (Espanha)
2018/09/06 ¿Por qué elegimos el melanoma uveal como proyecto de investigación para CIBERONC? https://www.gethi.org/contenidos/apartados/detalleApartado.aspx?idTipoApartado=i2%2F7o8SaukHJdF9r3vmW1Q%3D%3D&idCategoria=vcmxUUdhbPZVNx3%2FeyzeOQ%3D%3D&idApartado=d5XrZo1yr%2BR63bnHoZKy5A%3D%3D I Jornada GETHI CIBERONC
GETHI (Sevilla, Espanha)
2017 Rationale for the combination of Lurbinectedin/Trabectedin with Olaparib (Update) Incorporating EURO-EWING 99 and EWING 2008
EURO EWING Consortium – International Clinical Trials to Improve Survival from Ewing Sarcoma (london, Reino Unido)
2016/09/09 Dual targeting of Ewing sarcoma and the tumor microenvironment PROVABES/EORTC/DKTK/EEC_WP3&4 Meeting
Transcan-2 translational cancer research program (Essen, Alemanha)
2016 The potential application of exosomes in the clinical setting of Ewing Sarcoma
SEAP-IP (Spanish Society of Pathology) (Madrid, Espanha)
2014 Transcriptional downregulation of EWSR1-FLI1, induction of DNA damage and anti-IGF1R therapies in the treatment of Ewing Sarcoma http://www.ibis-sevilla.es/media/8087/Memoria_Anual_IBiS_2014.pdf XI Foro de Investigadores. Institute of Biomedicine of Seville
Insituto de Biomedicina de Sevilla (Sevilla, Espanha)
2010 Preclinical Evaluation of OSI-906 and Trabectedin effects on Ewing Sarcoma cells 1st Annual Eurosarc Meeting
EUROSARC (Treviso)

Orientação

Título / Tema
Papel desempenhado
Curso (Tipo)
Instituição / Organização
2023/08 - Atual Deciphering the role of membrane Nucleolin in newly engineered in vitro models of Prostate Cancer
Coorientador
Mestrado em Biotecnologia Farmacêutica (Mestrado)
Tumor Microenvironment and Targeted Therapies group-CNC-UC, Portugal
2021 - 2023 Desmoplastic Small Round Cell Tumor on the spotlight: Comprehensive molecular and functional characterization of new biomarkers and actionable targets
Coorientador
Instituto de Biomedicina de Sevilla, Espanha
2021/09 - 2022/06 Genomic and functional studies in clear cell sarcoma models
Coorientador
Biomedicina (Licenciatura/Bacharelato)
Universidad de Sevilla, Espanha
2020 - 2021 Uveal Melanoma: New Therapeutic Opportunities
Coorientador
Medicina y Cirugia (Licenciatura/Bacharelato)
Universidad de Sevilla-Facultad de Medicina, Espanha
2017 - 2021 Endoglin in Ewing Sarcoma: from the biological relevance to a clinical strategy
Coorientador
Instituto de Biomedicina de Sevilla, Espanha
2019 - 2020 New contributions on the Desmoplastic Small Round Cell Tumor: establishment of pre-clinical models for the identification of new targets and biomarkers
Coorientador
Master en Biomedicina (Mestrado)
Instituto de Biomedicina de Sevilla, Espanha
2018 - 2019 Endoglin/ALCAM as potential therapeutic targets in Clear Cell Sarcoma and Desmoplastic Small Round Cell Tumor
Coorientador
Universidad de Sevilla-Biomedicina (Licenciatura/Bacharelato)
2017 - 2018 Generation of knockout models for ALCAM of Uveal Melanoma and Ewing sarcoma
Coorientador
Biomedicina (Licenciatura/Bacharelato)
Universidad de LLeida Biomedicina , Espanha

Organização de evento

Nome do evento
Tipo de evento (Tipo de participação)
Instituição / Organização
2024/03/08 - 2024/03/08 Outreach activity at the Almas de Freire Primary School. Workshop: " O que são células?" "Como funcionam as vacinas?" "O que é a luz?" (2024/03/08 - 2024/03/08)
Oficina (workshop) (Coorganizador)
Universidade de Coimbra, Portugal
2023/02/11 - 2023/02/11 Outreach Activity at the Almas de Freire Priimary School: Workshop: "O que fazem os investigadores?" (2023/02/11 - 2023/02/11)
Oficina (workshop) (Coorganizador)
Escola Almas de Freire, Santa-Clara, Portugal

Universidade de Coimbra, Portugal

Participação em evento

Descrição da atividade
Tipo de evento
Nome do evento
Instituição / Organização
2022/02/11 - Atual CaixaResearch: Colaboración Dia Mundial del Cáncer infantil
Oficina (workshop)
Dia Mundial del Cáncer infantil
Obra Social La Caixa, Espanha
2020/02/11 - Atual Women In Science, February 11. “Meet Our Researchers” Science Dissemination Activities with children and high school students https://twitter.com/LabHuvr/status/1368943413706584073/photo/1
Seminário
Women In Science, February 11. “Meet Our Researchers”
2019 - Atual Science Dissemination Activities with children and high school students Science Fair-Seville https://twitter.com/LabHuvr/status/1129309616288993280/photo/1
Oficina (workshop)
Science Fair-Seville
2015/02/09 - Atual TUMOR MICROENVIRONMENT IN EWING SARCOMA. SEARCH FOR NEW DIAGNOSTIC TOOLS, AND THERAPEUTIC APPROACHES
Seminário
Seminario Program de Onco-Hematología y Genética
Hospital Universitario Virgen del Rocío, Espanha
2024/03/05 - 2024/03/05 Outreach activity at the UC Exploratório - Ciência Viva Coimbra for pre-schoolers " O que é o DNA?"
Oficina (workshop)
" O que é o DNA?"
UC Exploratório - Ciência Viva Coimbra , Portugal
2022/06/20 - 2022/06/23 Exploring the role of Endoglin in the aggressiveness of Ewing and Clear Cell Sarcoma Poster Presentation First author
Congresso
EACR 2022 Congress - Innovative Cancer Science
European Association For Cancer Research, Reino Unido
2022/06/20 - 2022/06/23 Optical Genome Mapping: Unravelling the genomic landscape of Solitary Fibrous Tumor Poster Presentation Collaborator author
Congresso
EACR 2022 Congress - Innovative Cancer Science: Translating Biology to Medicine
European Association For Cancer Research, Reino Unido
2022/06/20 - 2022/06/23 Desmoplastic Small Round Cell Tumor: modelling the disease Poster Presentation Senior author
Congresso
EACR 2022 Congress - Innovative Cancer Science: Translating Biology to Medicine
European Association For Cancer Research, Reino Unido
2021/12/10 - 2021/12/11 100 years Ewing Sarcoma: Learning from the past, Challenges for the future
Congresso
100 years Ewing Sarcoma: Learning from the past, Challenges for the future
Sarcoma Patients EuroNet EV, Alemanha
2018 - 2018 Unravelling endoglin as a potential therapeutic target for the treatment of uveal melanoma First author, poster presentation https://www.sciencedirect.com/science/article/pii/S2059702920320421
Congresso
EACR- 25
European Association For Cancer Research, Reino Unido

Arbitragem científica em revista

Nome da revista (ISSN) Editora
2020 - Atual Frontiers in Immunology and Frontiers in Oncology Frontiers
2022/12 - 2023/05 Frontiers in Immunology (1664-3224)

Comissão de avaliação

Descrição da atividade
Tipo de assessoria
Instituição / Organização Entidade financiadora
2021 - Atual Expert, external reviewer for the Spanish National Research Agency in 22 projects/grants

Curso / Disciplina lecionado

Disciplina Curso (Tipo) Instituição / Organização
2024 - Atual Mestrado Biotecnologia Farmaceutica-Módulo VI: Biofármacos na Prática Clínica Mestrado em Biotecnologia Farmacêutica (Mestrado) Universidade de Coimbra Faculdade de Farmácia, Portugal
2023 - Atual Mestrado Biotecnologia Farmaceutica-Módulo VI: Biofármacos na Prática Clínica Mestrado Biotecnologia Farmaceutica-Módulo VI (Mestrado) Universidade de Coimbra Faculdade de Farmácia, Portugal

Entrevista (jornal / revista)

Descrição da atividade Jornal / Forum
2019 Awarded EACR travel grant for an international short-stay. https://magazine.eacr.org/it-was-a-pleasure-ana-amaral-eacr-travel-fellow/ https://magazine.eacr.org/it-was-a-pleasure-ana-amaral-eacr-travel-fellow/

Membro de associação

Nome da associação Tipo de participação
2019 - Atual Member of the GETHI network. (Spanish group of Orphan and infrequent tumors) Membro
2018 - Atual CIBERONC network (Cancer Network Biomedical Research Center), Low Prevalence Tumours Program Membro Adscrito a Grupo de Trabalho
2017 - Atual Spanish group for sarcoma research (Grupo GEIS) Membro
2008 - Atual Ordem dos Farmacêuticos Mem
2016 - 2020 The European Association for Cancer Research EACR ambassador (From 2016-2020)
2016 - 2020 Associação Portuguesa de Investigação em Cancro ASPIC Membro

Membro de comissão

Descrição da atividade
Tipo de participação
Instituição / Organização
2019 - Atual Member of the Immunology central working
Membro
Centro de Investigación Biomédica en Red de Cáncer, Espanha

Tutoria

Tópico Nome do aluno
2020 - 2023 Desmoplastic Small Round Cell Tumor on the spotlight: Comprehensive molecular and functional characterization of new biomarkers and actionable targets Laura Lobo Selma
Distinções

Prémio

2023 HORIZON-WIDERA-2022-TALENTS-04
European Commission, Bélgica
2022 CIBERONC Travel Grant 2022-international fellowship
Centro de Investigación Biomédica en Red de Cáncer, Espanha
2019 "Juan de la Cierva" incorporation grant for a Post-Doctoral position
España Ministerio de Ciencia e Innovación, Espanha
2018 CIBERONC Travel grant for an international fellowship
Centro de Investigación Biomédica en Red de Cáncer, Espanha
2018 EACR travel grant for an international short-stay
European Association For Cancer Research, Reino Unido
2010 PhD grant funded by the Fundação para a Ciência e Tecnologia, Portugal
Fundação para a Ciência e a Tecnologia, Portugal